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Arthritis falls into two very broad categories, which are not
mutually exclusive. The most common is osteoarthritis, in
which a primary feature is degeneration of articular cartilage,
often accompanied by evidence of soft tissue inflammation
ranging from subtle to overt. The other broad category contains
inflammatory arthropathies, of which rheumatoid arthritis and
psoriatic arthritis are the most common examples.
There is no evidence to suggest that medications have a
significant influence on the natural history of osteoarthritis.
Management centres on diagnosis and qualified reassurance
regarding the generally slow tempo of osteoarthritis. (This
contrasts with the debilitating effects and destructive potential
of inflammatory arthropathies.) Patients with osteoarthritis
are advised to remain physically active without abusing affected
joints unnecessarily. Exercise prescriptions should be designed
to enhance and maintain general fitness and not focus narrowly
on the affected joint.1 Physiotherapists can provide advice
about exercises for general fitness and for maintaining the
strength and range of movement in affected joints.
Medication can be used to provide relief from pain. It may be
taken strategically before an activity which the patient
particularly wishes to maintain but is known to cause
discomfort. Paracetamol is the recommended first-line drug
for pain relief in osteoarthritis. This recommendation is based
on its greater safety compared to conventional non-steroidal
anti-inflammatory drugs (NSAIDs).
NSAIDs are recommended for second-line analgesia on an ‘as
required’ basis, with an accompanying warning about the
increased risk for potentially catastrophic gastrointestinal
adverse effects. While the relative risk for major upper
gastrointestinal bleeding is similar at all ages, the absolute risk
becomes far greater in the elderly. Indeed, the prevalence of
osteoarthritis in the elderly is so high (affecting most people
over 60 years of age) and the risk of upper gastrointestinal
events from NSAIDs (which generally result in hospitalisation
and sometimes death) is so substantial, that these unwanted
effects are a major public health problem.
How will this situation change with the introduction of selective
cyclo-oxygenase-2 (COX-2) inhibitors? We can expect a
significant reduction in hospitalisation and death from NSAID-
related upper gastrointestinal events. However, given the
demographics of NSAID use, what new risks might emerge?
A major unresolved question is the impact that COX-2 inhibitors
may have on the risk of thrombotic vascular events. This risk
is unlikely to be seen in short-term efficacy trials or early post-
marketing surveillance, but may only be identified in longer-
term epidemiological studies. To date, there is no clinical
evidence that such a risk exists. However, the selectivity of
COX-2 inhibitors gives some reasons for concern.
While COX-1 is the isoenzyme of COX involved in the
protective homeostasis of the stomach, where its inhibition is
generally undesirable, this isoenzyme is also responsible for
the production of thromboxane A2 by platelets. Thromboxane
A2 provides the prothombotic arm of platelet vascular
homeostasis and is counterbalanced by the endothelial
production of prostacyclin (PGI2) which is antithrombotic.
The balance of these mediators is such that adverse thrombotic
events generally constitute a greater hazard than uncontrolled
bleeding. This is why inhibition of platelet COX-1 by low dose
aspirin has a generally desirable effect when given to the
elderly and others at risk of thrombosis. COX-2 inhibitors do
not inhibit platelets and therefore do not have the antiplatelet
effect of low dose aspirin. This lack of antithrombotic protection
may be compounded by the inhibition of vascular prostacyclin
production by selective COX-2 inhibitors.2 This latter effect
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was shown recently and supports evidence that prostacyclin
synthesis is COX-2 dependent.3
Given available evidence and uncertainties, what provisional
advice should be given regarding the selective COX-2 inhibitors
in the symptomatic treatment of osteoarthritis? On the grounds
of cost alone, paracetamol should remain the drug of first
choice for those in whom it provides worthwhile symptomatic
relief. Patients for whom NSAIDs could provide significant
relief, were it not for unacceptable adverse effects or the risk
of upper gastrointestinal events, stand to benefit most from
COX-2 inhibitors. However, 500 low-risk patients may need
to be treated with a COX-2 inhibitor instead of an NSAID to
prevent one complicated ulcer.4 It has not yet been resolved
whether age itself constitutes a risk of upper gastrointestinal
events which is large enough to warrant selection of a
COX-2 inhibitor instead of a conventional NSAID.
However, it should be noted that low dose aspirin should be
continued where it is indicated and particularly so when a
selective COX-2 inhibitor is being used (see above). Since the
known variability between individuals in responsiveness to
particular NSAIDs seems to extend to COX-2 inhibitors,
patients who are changed from an NSAID that gives relief to
a COX-2 inhibitor may be disappointed. The advantage of
reduced risk for a seemingly remote contingency may be
associated with less complete control of symptoms.
With regard to the inflammatory arthropathies, it should be
noted that management of the prototypic disorder, rheumatoid
arthritis, has changed considerably.5 In recent onset
polyarthritis, there is an impetus for early intervention with
multiple therapies in patients at risk for ongoing disease and a
poor prognosis. While definitive therapeutic strategies are
yet to be determined, combinations such as methotrexate
(with a modest folate supplement), sulfasalazine and
hydroxychloroquine seem to hold most promise.6 NSAIDs,
including the COX-2 inhibitors, have a marginal role in these
protocols as they may reduce symptoms without improving
long-term outcomes, while displacing potentially more
effective longer-acting interventions. The early use of
prednisolone (or other glucocorticoids) is generally unhelpful,
as it confounds clinical assessment and, through its endocrine
action, is associated with inevitable unwanted effects. The
place of newer biological therapies such as etanercept has not
yet been resolved. On the grounds of cost alone, they are likely
to be restricted to patients who do not respond to conventional
long-acting drugs.
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Rifampicin and contraception
Editor, – The article ‘Common questions about the
management of meningococcal disease’ (Aust Prescr
1999;22:117-8) discusses the efficacy of oral
contraception following chemoprophylaxis for contacts
of meningococcal disease. I have discussed this issue with
the Family Planning Association and believe in-depth
advice on how to manage contraception while taking
rifampicin should be given to the contact.
Appropriate advice is: ‘In the case of short term concurrent
drug treatment, a barrier method should be used both during
treatment and for seven days after discontinuation. If this
would continue into the next oral contraceptive tablet-free
interval, the woman should skip the tablet-free interval and
start the next pack as soon as she has finished the pack in use.’1
This is an important issue, as advising women to stop oral
contraception or use another method for four weeks after
completion of chemoprophylaxis, increases the risk of
non-compliance and causes further stress to the contact.
It is also excessive and not necessary.
Giulietta Pontivivo
Registered Nurse
South East Sydney Public Health Unit
Sydney, NSW
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